A phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors

✍ Scribed by Craig A. Bunnell; Lynn Thompson; Lori Buswell; Ross Berkowitz; Michael Muto; Ellen Sheets; Lawrence N. Shulman

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 75 KB
• Volume: 82
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19980201)82:3<561::aid-cncr19>3.0.co;2-#

✦ Synopsis

Background:

Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. a phase i trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination.

Methods:

Patients with refractory, incurable solid tumors were entered on a 5-step phase i trial of ifosfamide, given in doses of 2-3 g/m2 intravenous (i.v.) bolus for 3 days with mesna support, and paclitaxel, given in doses of 135-190 g/m2 i.v. by continuous infusion over 24 hours. paclitaxel was given after the first dose of ifosfamide on day 1.

Results:

Twenty-three patients were treated, and the maximum tolerated dose was the highest planned dose level of the trial: ifosfamide, 3 g/m2/day i.v. for 3 days, and paclitaxel, 190 mg/m2 i.v. over 24 hours. hematologic toxicity was not dose-limiting, and although neutropenia occurred, it was brief (median, 2-4 days) and resulted in hospitalization for neutropenia and fever in only 7 of 111 courses of therapy. for patients treated at the highest dose level, only 1 of 50 courses of therapy resulted in hospitalization for neutropenia and fever. nonhematologic toxicity also was not severe and no significant neuropathy occurred. although patients entered into the study were heavily pretreated, responses were observed, particularly in patients with breast or ovarian carcinoma.

Conclusions:

Ifosfamide and paclitaxel can be administered safely in the doses used in this study and there are indications of significant antitumor effect. further studies are necessary to explore the antineoplastic activity of this regimen, particularly for patients with breast and ovarian carcinoma.